HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 09-27-2008, 01:00 PM   #1
Rich66
Senior Member
 
Rich66's Avatar
 
Join Date: Feb 2008
Location: South East Wisconsin
Posts: 3,431
Herpes Shows Promise for Killing Cancer



1. Herpes Shows Promise for Killing Cancer
A genetically engineered herpes virus, designed to kill cancer cells but leave normal tissue unharmed, has shown early promise in clinical tests, scientists say.
The idea of injecting cancer patients with a live virus may seem bizarre, but researchers believe viruses — which are experts at killing cells — could one day become a valuable addition to the medical armory against cancer.
The latest progress in a small study using MediGene AG’s virus NV1020 was presented at the annual European Society for Medical Oncology conference in Lugano, Switzerland.
NV1020 is a modified version of the herpes simplex virus, which causes cold sores. Its genetic make-up has been altered that so it only replicates in cancer cells, killing them in the process, and leaves ordinary cells alone.
The German biotech company had already announced positive results from an interim analysis of a 13-patient Phase III study of NV1020 in September, but efficacy data from a case study was unveiled for the first time at the Swiss meeting.
Axel Mescheder, MediGene’s research head, described the case of one very late-stage patient whose cancer had spread to 10 different places around the liver and four in the lungs.
He was given four weekly infusions of the virus followed by two cycles of chemotherapy, and six months after treatment scans showed that his liver tumors had nearly disappeared. The patient survived for 12 months following the intervention.
"The reduction in the tumor masses was really impressive in this patient. The hepatic [liver] masses almost disappeared,” Mescheder said in a statement.
"The results are really quite encouraging at this early stage.”
Treating cancer in the liver is notoriously difficult, and the prognosis for patients is very poor. Many people with colorectal cancer, in particular, face the risk that their cancer will metastasize, or spread, to the liver.
The encouraging results with the virus in early human studies follow tests in animals, which showed that NV1020 was effective at killing colorectal and liver cancer cells.



company site info:
http://www.medigene.de/englisch/ProjektHSV.php

__________________

Mom's treatment history (link)
Rich66 is offline   Reply With Quote
Old 10-01-2008, 10:03 AM   #2
RobinP
Senior Member
 
RobinP's Avatar
 
Join Date: Nov 2005
Posts: 943
Very Interesting Post Link. Appreciate It, Thanks! Many Innovative Drugs On The Horizon.
__________________
Robin
2002- dx her2 positive DCIS/bc TX Mast, herceptin chemo
RobinP is offline   Reply With Quote
Old 10-02-2008, 06:44 AM   #3
Hopeful
Senior Member
 
Join Date: Aug 2006
Posts: 3,380
Food for thought

This 2004 study of the mechanisms of action of neoadjuvant Herceptin, states:

"Interestingly, it may be worth to note that, shortly before diagnosis of breast carcinoma, the patient who underwent a complete pathological remission experienced a herpes virus infection that might have increased NK activity, as reported recently (11) "

http://clincancerres.aacrjournals.or...ull/10/17/5650

Hopeful
Hopeful is offline   Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 02:38 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter